합성의약품으로 호전되지 않은 소화기 증상 환자(KCD K-코드)에 대한 반하사심탕 제제 병용의 효과 : 후향적 차트 분석
Effectiveness of Additional Administration of a Banha-sasim-tang Formulation to Patients with Gastrointestinal Symptoms (KCD K-code) Not Improved by Western Medicines: A Retrospective Chart Review
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objectives: The aim of this study was to evaluate the effectiveness of additional administration of Banha-sasim-tang formulation to patients with gastrointestinal symptoms that did not improve with Western medicines. Methods: The patients who met the inclusion and exclusion criteria were analyzed retrospectively. A paired t-test was performed on the Nepean Dyspepsia Index-Korean version (NDI-K) scores before and after administering the Banha-sasim-tang formulation. Results: A total of 27 subjects were included. The mean duration of taking the Banha-sasim-tang formulation was 15.6±3.1 days. The most commonly used Western medicine before taking the Banha-sasim-tang formulation was rebamipide. The means of the NDI-K score were 57.4±21.8 before administering Banha-sasim-tang formulation and 34.9±16.5 after administration, and the difference was statistically significant (p<0.0001). No serious side effects were encountered while taking the Banha-sasim-tang formulation. Conclusions: For patients whose gastrointestinal symptoms do not improve with Western medicines, additional administration of Banha-sasim-tang formulation may be an option. However, as this study is a retrospective chart review, prospective, large-scale, double-blind studies are needed in the future.
Abstract
Objectives: The aim of this study was to evaluate the effectiveness of additional administration of Banha-sasim-tang formulation to patients with gastrointestinal symptoms that did not improve with Western medicines. Methods: The patients who met the inclusion and exclusion criteria were analyzed retrospectively. A paired t-test was performed on the Nepean Dyspepsia Index-Korean version (NDI-K) scores before and after administering the Banha-sasim-tang formulation. Results: A total of 27 subjects were included. The mean duration of taking the Banha-sasim-tang formulation was 15.6±3.1 days. The most commonly used Western medicine before taking the Banha-sasim-tang formulation was rebamipide. The means of the NDI-K score were 57.4±21.8 before administering Banha-sasim-tang formulation and 34.9±16.5 after administration, and the difference was statistically significant (p<0.0001). No serious side effects were encountered while taking the Banha-sasim-tang formulation. Conclusions: For patients whose gastrointestinal symptoms do not improve with Western medicines, additional administration of Banha-sasim-tang formulation may be an option. However, as this study is a retrospective chart review, prospective, large-scale, double-blind studies are needed in the future.
참고문헌 (21)
- Yoon SH, "Evaluation for therapeutic effectiveness of Banwhasashim-tang in functional dyspepsia", J Int Korean Med, 24(2), pp.329~336 (2003)
- Park JW, "Banha-sasim-tang as an herbal formula for the treatment of functional dyspepsia:a randomized, double-blind, placebo-controlled, two-center trial", Trials, 11(1), pp.1~7 (2010)
- Xu G, "Treatment of reflux laryngopharyngitis with modified banxia xiexin tang (Pinellia decoction for draining the heart)--a report of 40 cases", Journal of traditional Chinese medicine=Chung i tsa chih ying wen pan, 26(2), pp.127~131 (2006)
- Shin MR, "Anti-apoptotic effect of banhasasim-tang on chronic acid reflux esophagitis", World journal of gastroenterology, 23(25), pp.4644~4653 (2017)
- Wang Y, "Clinical Observation of Reflux Esophagitis Treated with Modified BanxiaXiexin Decoction and Rabeprazole", World Journal of Integrated Traditional and Western Medicine, 8(2), pp.200~202 (2013)
- 김윤정, "의약품 지출 비용에 미치는 영향 요인 - 한국의료패널자료를 활용하여", 한국콘텐츠학회 논문지, 18(4), pp.664~676 (2018), 한국콘텐츠학회[DOI]
- 송경호, "기능성 소화불량증", 정신신체의학, 24(1), pp.3~8 (2016), 한국정신신체의학회
- 오정환, "기능성 소화불량증", 대한소화기학회지, 73(2), pp.77~83 (2019), 대한소화기학회
- 백가연, "소청룡탕 제조방법에 따른 성분 및 생리활성 비교", 생약학회지, 49(4), pp.349~361 (2018), 한국생약학회
- Lee SY, "Validation of the Nepean dyspepsia index-Korean version", Kor J Neurogastroenterol Mot, 9(suppl), pp.48S~ (2003)
- 최진용, "임상실습 학생을 대상으로 한 위전도검사와 Nepean Dyspepsia Index(NDI) 설문검사와의 연관성 연구", 대한한방내과학회지, 39(4), pp.732~740 (2018), 대한한방내과학회
- 이오영, "위장관 운동 조절 약물", 대한의사협회지, 52(9), pp.920~927 (2009), 대한의사협회
- Stolfi C, "Mechanisms of action of non-steroidal anti-inflammatory drugs (NSAIDs) and mesalazine in the chemoprevention of colorectal cancer", International journal of molecular sciences, 14(9), pp.17972~17985 (2013)
- Talley NJ, "Validity of a new quality of life scale for functional dyspepsia:a United States multicenter trial of the Nepean Dyspepsia Index", The American journal of gastroenterology, 94(9), pp.2390~2397 (1999)
- Arinton IG, "Randomized clinical trial of omeprazole and ranitidine using Indonesian translated Nepean Dyspepsia Index", J Intern Med, 7, pp.170~177 (2006)
- Hashash JG, "Clinical trial: a randomized controlled cross-over study of flupenthixol+ melitracen in functional dyspepsia", Alimentary pharmacology & therapeutics, 27(11), pp.1148~1155 (2008)
- Talley NJ, "Development of a new dyspepsia impact scale: the Nepean Dyspepsia Index", Alimentary pharmacology & therapeutics, 13(2), pp.225~235 (1999)
- 신혜원, "Drug-Induced Parkinsonism", Journal of Clinical Neurology, 8(1), pp.15~21 (2012), 대한신경과학회
- Shim YH, "Herbal medicine treatment for drug-induced parkinsonism", The Journal of Alternative and Complementary Medicine, 21(5), pp.273~280 (2015)
- 조유경, "기능성 소화불량증의 삶의 질에 대한 모사프리드의 효과", 대한소화기학회지, 43(3), pp.160~167 (2004), 대한소화기학회
- 이정원, "기능성 소화불량증 환자에 대한 서방형 UIC201609", UIC201610 병용요법의 유효성 및 안전성을 비교평가하기 위한 다기관, 무작위배정, 위약대조 임상시험: 예비 보고, 2021, pp.77(4), 171~178[DOI]